Cargando…
Systemic Therapy for Advanced Soft Tissue Sarcomas
Soft tissue sarcomas (STS) are a rare, heterogeneous group of solid tumors in need of improved therapeutic options. First-line chemotherapy is considered the current standard of care for patients with advanced, symptomatic STS, but the median survival is only 8 to 12 months. Efforts to increase resp...
Autor principal: | Riedel, Richard F |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wiley Subscription Services, Inc., A Wiley Company
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412982/ https://www.ncbi.nlm.nih.gov/pubmed/21837668 http://dx.doi.org/10.1002/cncr.26415 |
Ejemplares similares
-
Molecular targeted therapy for advanced or metastatic soft tissue sarcoma
por: Yuan, Jin, et al.
Publicado: (2021) -
Pazopanib in advanced soft tissue sarcomas
por: Lee, Alex T. J., et al.
Publicado: (2019) -
Making progress in a rare disease: emerging therapeutics in soft tissue sarcomas
por: Choe, Jennifer, et al.
Publicado: (2018) -
Pazopanib in the management of advanced soft tissue sarcomas
por: Cranmer, Lee D, et al.
Publicado: (2016) -
Trabectedin for advanced soft tissue sarcomas: optimizing use
por: Reid, Alison, et al.
Publicado: (2014)